会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • 4-phenyl-pyrimidine derivatives
    • 4-苯基 - 嘧啶衍生物
    • US06274588B1
    • 2001-08-14
    • US09575382
    • 2000-05-22
    • Michael BösGuido GalleyThierry GodelTorsten HoffmannWalter HunkelerPatrick SchniderHeinz Stadler
    • Michael BösGuido GalleyThierry GodelTorsten HoffmannWalter HunkelerPatrick SchniderHeinz Stadler
    • C07D23924
    • C07D239/28C07D239/34C07D239/38C07D239/42C07D239/48C07D401/04
    • The invention provides compounds of the formula wherein R1 is hydrogen or halogen; R2 is hydrogen, halogen, lower alkyl or lower alkoxy; R1 and R2 may together be —CH═CH—CH═CH—, wherein R1 and R2 together with the two carbon ring atoms to which they are attached form a fused ring; R3 is halogen, trifluoromethyl, lower alkyl or lower alkoxy; R4/R4′ are each independently hydrogen or lower alkyl; R5 is lower alkyl, lower alkoxy, amino, phenyl, hydroxy-lower alkyl, cyano-lower alkyl, carbamoyl-lower alkyl, pyridyl, pyrimidyl, —(CH2)n-piperazinyl, which is optionally substituted by one or two lower alkyl groups or by hydroxy-lower alkyl, —(CH2)n-morpholinyl, —(CH2)n-piperidinyl, —(CH2)n+1-imidazolyl, lower alkyl-sulfanyl, lower alkyl-sulfonyl, benzylamino, —NH—(CH2)n+1N(R4″)2, —(CH2)n+1N(R4″)2, —O—(CH2)n+1-morpholinyl, —O—(CH2)n+1-piperidinyl or —O—(CH2)n+1N(R4″)2, wherein R4″ is hydrogen or lower alkyl; and n is 0-2; X is —C(O)N(R4″)— or —N(R4″)C(O)—; and to pharmaceutically acceptable acid addition salts thereof. It has been shown that the compounds have a good affinity to the NK-1 receptor and may therefore used for the treatment of diseases related to this receptor.
    • 本发明提供的化合物,其中R 1是氢或卤素; R 2是氢,卤素,低级烷基或低级烷氧基; R 1和R 2一起可以是-CH = CH-CH = CH-,其中R 1和R 2与两个碳环 它们所连接的原子形成稠环; R3是卤素,三氟甲基,低级烷基或低级烷氧基; R4 / R4'各自独立地是氢或低级烷基; R5是低级烷基,低级烷氧基,氨基,苯基,羟基 - 低级 烷基,氰基 - 低级烷基,氨基甲酰基 - 低级烷基,吡啶基,嘧啶基, - (CH2)n-哌嗪基,其任选被一个或两个低级烷基或羟基 - 低级烷基取代, - (CH 2) - (CH 2)n - 哌啶基, - (CH 2)n + 1-咪唑基,低级烷基 - 硫烷基,低级烷基磺酰基,苄基氨基,-NH-(CH 2)n + n + 1N(R4“)2,-O-(CH2)n + 1-吗啉基,-O-(CH2)n + 1-哌啶基或-O-(CH2)n + 1N(R4” 其中R4“是氢或低级烷基; 和n为0-2; X为-C(O)N(R4“) - 或-N(R4”)C(O) - ;以及其药学上可接受的酸加成盐。 对NK-1受体具有良好的亲和性,因此可用于治疗与该受体有关的疾病。
    • 6. 发明授权
    • 3-phenyl-pyridine-derivatives
    • 3-苯基 - 吡啶衍生物
    • US06225316B1
    • 2001-05-01
    • US09505359
    • 2000-02-16
    • Michael BösGuido GalleyThierry GodelTorsten HoffmannWalter HunkelerPatrick SchniderHeinz Stadler
    • Michael BösGuido GalleyThierry GodelTorsten HoffmannWalter HunkelerPatrick SchniderHeinz Stadler
    • A61K3150
    • C07D213/75C07D213/38C07D213/81
    • The invention relates to compounds of the formula wherein R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; R1 is hydrogen or halogen; or R and R1 may be together —CH═CH—CH═CH—; R2 is hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; R3 is hydrogen, lower alkyl or form a cycloalkyl group; R4 is hydrogen, —N(R5)2, —N(R5)S(O)2-lower alkyl, —N(R5)C(O)R5 or a cyclic tertiary amine of the group R5 is, independently from each other, hydrogen, C3-6-cycloalkyl, benzyl or lower alkyl; R6 is hydrogen, hydroxy, lower alkyl, —N(R5)CO-lower alkyl, hydroxy-lower alkyl, cyano, —CHO or a 5- or 6 membered heterocyclic group, optionally bonded via an alkylene group, X is —C(O)N(R5)—, —(CH2)mO—, —(CH2)mN(R5)—, —N(R5)C(O)—, or —N(R5)(CH2)m—; n is 0-4; and m is 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. It has been shown that the above mentioned compounds have a good affinity to the NK-1 receptor.
    • 本发明涉及式Ⅳ的化合物,其中R是氢,低级烷基,低级烷氧基,卤素或三氟甲基; R 1是氢或卤素; 或R 1可以是-CH = CH-CH = CH-; R 2是氢,卤素,三氟甲基,低级烷氧基或氰基; R 3是氢,低级烷基或形成环烷基; R 4是氢,-N(R 5) 2,-N(R 5)S(O)2-低级烷基,-N(R 5)C(O)R 5或基团R 5的环状叔胺彼此独立地为氢,C 3-6 - 环烷基,苄基 或低级烷基; R6是氢,羟基,低级烷基,-N(R5)CO-低级烷基,羟基 - 低级烷基,氰基,-CHO或5-或6-元杂环基,任选地通过亚烷基键合,X 是(C) - (CH 2)m O - , - (CH 2)m N(R 5) - , - N(R 5)C(O) - 或-N(R 5) - ; n为0-4; 和m为1或2;以及其药学上可接受的酸加成盐。已经显示上述化合物对NK-1受体具有良好的亲和力。
    • 7. 发明授权
    • 5-phenyl-pyrimidine derivatives
    • 5-苯基 - 嘧啶衍生物
    • US06756380B1
    • 2004-06-29
    • US09575789
    • 2000-05-22
    • Michael BösGuido GalleyThierry GodelTorsten HoffmannWalter HunkelerPatrick SchniderHeinz Stadler
    • Michael BösGuido GalleyThierry GodelTorsten HoffmannWalter HunkelerPatrick SchniderHeinz Stadler
    • C07D23932
    • C07D239/28C07D239/34C07D239/42C07D239/47C07D239/48
    • Compounds of the general formula are described: wherein R1 is hydrogen or halogen; R2 is hydrogen, halogen, lower alkyl or lower alkoxy; R3 is halogen, trifluoromethyl, lower alkoxy or lower alkyl; R4/R4′are each independently hydrogen or lower alkyl; R5 is lower alkyl, lower alkoxy, amino, hydroxy, hydroxy-lower alkyl, —(CH2)n-piperazinyl, optionally substituted by lower alkyl, —(CH2)n-morpholinyl, —(CH2)n+1-imidazolyl, —O—(CH2)n+1-morpholinyl, —O—(CH2)n+1-piperidinyl, lower alkyl-sulfanyl, lower alkyl-sulfonyl, benzylamino, —NH—(CH2)n+1N(R4″)2, —(CH2)n—NH—(CH2)n+1N(R4″)2, —(CH2)n+1N(R4″)2, or —O—(CH2)n+1N(R4″)2, wherein R4″ is hydrogen or lower alkyl; R6 is hydrogen; R2 and R6 or R1 and R6 may together be —CH═CH—CH═CH—, wherein R2 and R6 or R1 and R6, respectively, together with the two carbon ring atoms to which they are attached form a fused ring, with the proviso that n for R1 is 1; n is independently 0-2; and X is —C(O)N(R4″)— or —N(R4″)C(O)—; and pharmaceutically acceptable acid addition salts thereof.
    • 描述通式的化合物:其中R 1是氢或卤素; R 2是氢,卤素,低级烷基或低级烷氧基; R 3是卤素,三氟甲基,低级烷氧基或低级烷基; R 4 R 5是氢或低级烷基; R 5是低级烷基,低级烷氧基,氨基,羟基,羟基 - 低级烷基, - (CH 2)n - 哌嗪基,任选被低级烷基取代, (CH2)n-吗啉基, - (CH2)n + 1-咪唑基,-O-(CH2)n + 1-吗啉基,-O-(CH2)n + 1-哌啶基,低级烷基 - ,苄基氨基,-NH-(CH 2)n + 1N(R 4“)2, - (CH 2)n -NH-(CH 2)n + 1N(R 4”)2, - (CH 2) n + 1N(R 4“)2或-O-(CH 2)n + 1N(R 4”)2,其中R 4“是氢或低级烷基; R 6' R 2和R 6或R 1和R 6可以一起为-CH = CH-CH = CH-,其中R 2和R 6或R 1为氢; 和R 6分别与它们所连接的两个碳环原子一起形成稠合环,条件是R 1的n为1; n独立地为0-2; 和X是-C(O)N(R“”) - 或-N(R“”)C(O) - ;及其药学上可接受的酸加成盐。